Fujian Aonong Biological Technology Group Incorporation Limited (SHA:603363)
China · Delayed Price · Currency is CNY 4.040
-0.030 (-0.74%)
Feb 13, 2026, 3:00 PM CST
SHA:603363 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 8,141 | 8,731 | 19,432 | 21,581 | 18,013 | 11,504 |
Other Revenue | 31.41 | 31.41 | 25.21 | 31.93 | 25.56 | 12.72 |
| 8,173 | 8,763 | 19,458 | 21,613 | 18,038 | 11,517 | |
Revenue Growth (YoY) | -27.07% | -54.96% | -9.97% | 19.82% | 56.62% | 98.98% |
Cost of Revenue | 7,584 | 8,367 | 20,767 | 20,956 | 18,209 | 9,531 |
Gross Profit | 588.52 | 395.6 | -1,309 | 657.28 | -170.49 | 1,986 |
Selling, General & Admin | 682.77 | 1,129 | 1,071 | 1,073 | 944.98 | 677.96 |
Research & Development | 48.36 | 54.47 | 148.86 | 161.67 | 113.88 | 65.36 |
Other Operating Expenses | 16.43 | 6.05 | 24.6 | 25.76 | -2.41 | 16.78 |
Operating Expenses | 790.91 | 1,245 | 1,291 | 1,285 | 1,101 | 822.49 |
Operating Income | -202.39 | -849.59 | -2,600 | -628.17 | -1,272 | 1,163 |
Interest Expense | -415.56 | -650.95 | -549.99 | -505.83 | -418.77 | -177.15 |
Interest & Investment Income | 2,486 | 2,043 | 5.19 | 5.94 | 3.76 | 9.74 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -1.41 | -6.85 | -0.34 | 0.05 |
Other Non Operating Income (Expenses) | 34.7 | -53.81 | -52.18 | -75.77 | -20.85 | -40.51 |
EBT Excluding Unusual Items | 1,903 | 488.56 | -3,198 | -1,211 | -1,708 | 955.48 |
Impairment of Goodwill | -35.39 | -35.39 | -34.66 | -36.51 | -12.14 | -4.31 |
Gain (Loss) on Sale of Investments | -21.6 | -30.32 | -4.07 | -119.76 | -68.86 | -23.69 |
Gain (Loss) on Sale of Assets | -85.9 | 5.59 | -49.74 | -9.41 | -25.09 | -15.46 |
Asset Writedown | -98.51 | -98.51 | -424.3 | -2.76 | -7.63 | - |
Other Unusual Items | -245.43 | -245.43 | 29.37 | 84.1 | - | 58.49 |
Pretax Income | 1,416 | 84.49 | -3,682 | -1,295 | -1,822 | 970.52 |
Income Tax Expense | -39.44 | 21.4 | 87.05 | -69.21 | 29.34 | -23.09 |
Earnings From Continuing Operations | 1,455 | 63.09 | -3,769 | -1,226 | -1,851 | 993.61 |
Minority Interest in Earnings | 356.81 | 516.25 | 117.86 | 187.46 | 331.05 | -420.62 |
Net Income | 1,812 | 579.35 | -3,651 | -1,038 | -1,520 | 572.99 |
Net Income to Common | 1,812 | 579.35 | -3,651 | -1,038 | -1,520 | 572.99 |
Net Income Growth | - | - | - | - | - | 1865.27% |
Shares Outstanding (Basic) | 2,152 | 865 | 867 | 775 | 650 | 603 |
Shares Outstanding (Diluted) | 2,152 | 865 | 867 | 775 | 650 | 630 |
Shares Change (YoY) | 146.92% | -0.29% | 11.91% | 19.30% | 3.15% | 7.98% |
EPS (Basic) | 0.84 | 0.67 | -4.21 | -1.34 | -2.34 | 0.95 |
EPS (Diluted) | 0.84 | 0.67 | -4.21 | -1.34 | -2.34 | 0.91 |
EPS Growth | - | - | - | - | - | 1720.00% |
Free Cash Flow | -776.26 | -379.46 | 472.23 | -835.31 | -2,184 | -2,887 |
Free Cash Flow Per Share | -0.36 | -0.44 | 0.55 | -1.08 | -3.36 | -4.58 |
Dividend Per Share | - | - | - | - | - | 0.227 |
Gross Margin | 7.20% | 4.52% | -6.73% | 3.04% | -0.95% | 17.24% |
Operating Margin | -2.48% | -9.70% | -13.36% | -2.91% | -7.05% | 10.10% |
Profit Margin | 22.18% | 6.61% | -18.76% | -4.80% | -8.43% | 4.98% |
Free Cash Flow Margin | -9.50% | -4.33% | 2.43% | -3.86% | -12.11% | -25.06% |
EBITDA | 231.47 | -248.73 | -1,776 | 232.72 | -574.94 | 1,491 |
EBITDA Margin | 2.83% | -2.84% | -9.13% | 1.08% | -3.19% | 12.94% |
D&A For EBITDA | 433.86 | 600.86 | 823.53 | 860.9 | 696.72 | 327.21 |
EBIT | -202.39 | -849.59 | -2,600 | -628.17 | -1,272 | 1,163 |
EBIT Margin | -2.48% | -9.70% | -13.36% | -2.91% | -7.05% | 10.10% |
Effective Tax Rate | - | 25.33% | - | - | - | - |
Revenue as Reported | 8,173 | 8,763 | 19,458 | 21,613 | 18,038 | 11,517 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.